Concepedia

Author

Nathan Hambly

McMaster UniversityORCID

Also Known As

Mark Larch, N. Hambly, NATHAN HAMBLY, Nathan Hambly

119

Publications

1.6K

Citations

21

H-Index

9

Concepts

All Affiliations

McMaster UniversityUniversity of British ColumbiaUniversity of CalgaryUniversity of TorontoCentre Hospitalier de l’Université de Montréal
NH

About

Nathan Hambly is an author at McMaster University specializing in pulmonary disease, medicine, and pulmonary fibrosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

123

2

Pulmonary Disease

4

4

123

3

Epidemiology

1

1

69

4

Pulmonary Medicine

1

1

11

5

Obesity

1

1

69

Nathan Hambly

×

25

Publications

991

Citations

17

H-Index

YearCitations

Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Nathan Hambly, Mohammed A. Farooqi, Anna Dvorkin‐Gheva,

European Respiratory Journal

2022

171

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis

Jolene H. Fisher, Martin Kolb, Mohmmed Algamdi,

BMC Pulmonary Medicine

2019

102

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry

Christopher J. Ryerson, Benjamin Tan, Charlene D. Fell,

Canadian Respiratory Journal

2016

71

Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease

Alessia Comes, Alyson W. Wong, Jolene H. Fisher,

CHEST Journal

2021

69

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension

Pierre‐Simon Bellaye, Toyoshi Yanagihara, Elise Granton,

European Respiratory Journal

2018

63

Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease

Amy Po Yu Tsai, Seo Am Hur, Alyson W. Wong,

Thorax

2020

60

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

Abdullah Sakkat, Gerard Cox, Nader Khalidi,

Respiratory Research

2022

50

High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study

Christopher J. Ryerson, Pat G. Camp, Neil D. Eves,

Annals of the American Thoracic Society

2016

47

Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study

Sabina A. Guler, Seo Am Hur, Michael K. Stickland,

Thorax

2021

42

Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study

Mohammed A. Farooqi, Sachi O’Hoski, Sarah Goodwin,

Respirology

2021

39

Page 1